To cite this paper use one of the standards below:
Currently, 60% of all drugs in the market bind to G-protein coupled receptors (GPCR)¹. Among GPCRs, adenosine-subtype A2B has raised interest because it is related to diseases such as cancer and sickle cell disease². However, this target doesn’t have a crystallographic structure available. Thus, we built the receptor 3D model on SWISS-Model server3(template PDB:5IU7; 60.26% identity) with adequate structural parameters: GMQE (0.75) and QMEAN(-3.12). Through CHARMM-GUI server, we inserted it into a lipid membrane and ran a molecular dynamics (MD) simulation on GROMACS 5.1.24: CHARMM forcefield; pH=7.4; NVT; T=303.15K; t=100ns. We compared the stability of our systems: A2B and A2B-antagonist. The deviation and fluctuation data were: 3.14x10-1± 5.81x10-2nm (A2B) and 1.61x10-1± 5.31x10-3nm (A2B-antagonist) and 1.11x10-1± 8.45x10-2nm (A2B) and 6.89x10-2± 2.61x10-2nm (A2B-antagonist). The antagonist stabilizes binding-site residues when compared to the A2B form, making the system reliable to be used in next virtual screening steps to identify new promising A2B antagonists.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper